Idiopathic (Essential) Hypertension – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension – Pipeline Review, H2 2016’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension

The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects

The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Actelion Ltd

Bayer AG

Chong Kun Dang Pharmaceutical Corp.

Daiichi Sankyo Company, Limited

Eli Lilly and Company

HanAll Biopharma Co., Ltd.

Innopharmax Inc.

Lee's Pharmaceutical Holdings Limited

PhaseBio Pharmaceuticals, Inc.

Quantum Genomics SA

Takeda Pharmaceutical Company Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Idiopathic (Essential) Hypertension Overview 8

Therapeutics Development 9

Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9

Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10

Idiopathic (Essential) Hypertension - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Idiopathic (Essential) Hypertension - Products under Development by Companies 14

Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 15

Actelion Ltd 15

Bayer AG 16

Chong Kun Dang Pharmaceutical Corp. 17

Daiichi Sankyo Company, Limited 18

Eli Lilly and Company 19

HanAll Biopharma Co., Ltd. 20

Innopharmax Inc. 21

Lee's Pharmaceutical Holdings Limited 22

PhaseBio Pharmaceuticals, Inc. 23

Quantum Genomics SA 24

Takeda Pharmaceutical Company Limited 25

Idiopathic (Essential) Hypertension - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

(amlodipine besylate + candesartan cilexetil) - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

(atorvastatin calcium + losartan potassium) - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(candesartan cilexetil + nifedipine) - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

azilsartan medoxomil - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

carvedilol phosphate CR - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CS-3150 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

lisinopril - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

LY-2623091 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

PB-1046 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

PB-1120 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

QGC-001 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

rostafuroxin - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Idiopathic (Essential) Hypertension - Dormant Projects 57

Idiopathic (Essential) Hypertension - Product Development Milestones 59

Featured News & Press Releases 59

Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 59

Jun 12, 2013: Lee’s Pharma Enrolls First Patient in Phase IIb Clinical Trial of Rostafuroxin in Italy 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Idiopathic (Essential) Hypertension – Pipeline by Actelion Ltd, H2 2016 15

Idiopathic (Essential) Hypertension – Pipeline by Bayer AG, H2 2016 16

Idiopathic (Essential) Hypertension – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 17

Idiopathic (Essential) Hypertension – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 18

Idiopathic (Essential) Hypertension – Pipeline by Eli Lilly and Company, H2 2016 19

Idiopathic (Essential) Hypertension – Pipeline by HanAll Biopharma Co., Ltd., H2 2016 20

Idiopathic (Essential) Hypertension – Pipeline by Innopharmax Inc., H2 2016 21

Idiopathic (Essential) Hypertension – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 22

Idiopathic (Essential) Hypertension – Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 23

Idiopathic (Essential) Hypertension – Pipeline by Quantum Genomics SA, H2 2016 24

Idiopathic (Essential) Hypertension – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Idiopathic (Essential) Hypertension – Dormant Projects, H2 2016 57

Idiopathic (Essential) Hypertension – Dormant Projects (Contd..1), H2 2016 58

List of Figures

List of Figures

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Top 10 Targets, H2 2016 28

Number of Products by Stage and Top 10 Targets, H2 2016 28

Number of Products by Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports